Pressure BioScience (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables, and platform technology solutions to the worldwide biotechnology,
biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage
industries, on Tuesday announced that one of its two pending merger partners,
Cannaworx, Inc., is substantially expanding its sales and distribution network
through a letter of intent (“LOI”) to acquire Louisiana-based Five Leaf Labs
(“FLL”). FLL recently released its first set of CBD-infused products to the
U.S. market. “We attribute the success of our initial launch to both the high
quality of our hemp source supply and processing methods, and to the
effectiveness of our well-trained, knowledgeable and experienced network of
over 50 sales representatives spanning 21 states,” Five Leaf Laboratories
founder and president Keyon Janani stated in the news release. Cannaworx and
its principals have twelve products being prepared for market launch over the
next year, including two novel products that employ the company’s
patented/patent pending, full and partial spectrum, hemp-derived
phytocannabinoid formulations for pain relief. This acquisition is critically
timed for Cannaworx, as it is anticipating the market launch of its first two
products over the coming weeks. “From the day we met Keyon, we have been
thoroughly impressed with him, the rest of the FLL team, their innovative
product line, and of course their very strong and capable sales and
distribution network. In addition, we are also motivated by the compelling
standards of quality that drive Keyon and his team. For example, every product
batch at FLL goes through rigorous third-party review and certification for
content, consistency, and potency, from one of the most respected academic
institutions in the U.S. We are pleased to be adding Five Leaf Laboratories to
the Cannaworx family,” Cannaworx co-founder and president Dr. Bobby Ghalili
stated in the news release.
To view the full press release, visit http://ibn.fm/lCV7J
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life-sciences industry. The company’s products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented,
enabling technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s
primary focus is in the development of PCT-based products for biomarker and
target discovery, drug design and development, biotherapeutics characterization
and quality control, soil and plant biology, forensics and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of its pressure-based technologies in the following areas: (1) the use of
its recently acquired, patented technology from BaroFold Inc. (the “BaroFold”
technology) to allow entry into the biopharma contract services sector, and (2)
the use of its recently patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and (ii) prepare
higher-quality, homogenized, extended shelf-life or room-temperature, stable,
low-acid liquid foods that cannot be effectively preserved using existing
nonthermal technologies. For more information, visit the company’s website
at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
